InFocus featuring Dr. Neil Forbes (UMass Cancer Research)

Western Massachusetts News, Weather & Sports
497 followers
148 Video Views·Jun 14, 2026
InFocus featuring Dr. Neil Forbes (UMass Cancer Research)
From the 22 News Plus Studio,
this is 22 News In Focus with Patrick Berry. Hello everyone and welcome to this edition of
In Focus. I'm your host Patrick Berry. When you think of, you know, major cancer research,
you probably think of Dana-Farber, the Mayo Clinic, Stanford University, or a wealth of other
places around the country and around the globe. But right here in Western Mass, just up the road
on the campus of University of Massachusetts Amherst, groundbreaking research is taking place.
I'm so excited today because joining me across the desk is Dr. Neil Forbes. He's a professor
of chemical and biomolecular engineering at the University of Massachusetts and Amherst.
And he is working on some amazing research, which is why he's sitting in the chair today.
And we'll get into that in just a minute. So Dr. Forbes, thank you so very much for joining me.
When I got word about what you were doing, my mind was absolutely blown.
I'm going to summarize it, but then we will get into how it happened. You're using salmonella
to target two of the most deadly cancers out there, liver cancer and pancreatic cancer.
That's a one-sentence summary, but it had to have taken years for you to understand how
the cancer tumors work, salmonella works, and bring them together to
one to fight the other. So let's go back in time. How long have you been working on the
salmonella aspect of it? So the salmonella I've been working on since 2001, so 25 years.
Wow. A long time.
A long time. Yeah.
Okay. So at what point in time, and it's funny because I said this to one of my co-workers,
at what point in time in your head did you go, wonder how salmonella would attack cancer?
Well, I stole it.
Why salmonella, not malaria, not one of the other many, many, many different parts.
Okay. So there's two pieces to this. When I was a little kid, I had this weird dream that you
could take one disease and have it help solve another disease. And I was like, something that
I always wanted to do, and I want to do something with genetics back in the eighties. And I was
like, well, how could you use this? And then I found out that someone had developed a salmonella
that was non-toxic and accumulated in tumors. So it's not your basic raw chicken salmonella.
It's not basic salmonella. So the thing that makes salmonella dangerous has been taken out of it.
So it's kind of been de-toothed. But we use a lot of its natural aspects in its therapy and we
modify it a lot. So we do a lot of genetic engineering to make it so that it's safer
and more effective. So is this the reduced risk salmonella, is that normally used in medical
research? It has not been used in the clinic yet. It's still all being used preclinically.
There has been clinical trials tried with it. So it has been used in people.
So the use of salmonella isn't new. It's been used for years.
People might find this interesting. We've been thinking about bacteria and cancer since before
we understood what bacteria were. There are studies going back to the 1700s when they actually found
that people got infections, they got disease, they'd get fevers, and sometimes their tumors
would disappear. So this has actually been known about since, and then there was a therapy
developed in the 1880s that used bacteria to clear tumors. Yeah. So this is not, I mean,
it's not no offense to you. This is not new. It's not new in that way. What changed, of course,
is in the 80s, we had this whole revolution to genetic engineering, synthetic biology,
the ability to manipulate them to do what we want them to do. And so that started in the late 90s,
they came back and then relooked at different species that accumulated in tumors. And then
from there, I thought, oh, you know, I'm an engineer. And the engineering aspect is sort
of twofold. A, lots of drugs don't do well. They don't get into tumors and get where they need to
go. So can we manipulate bacteria to do this? And so the idea that I had was-
Coming back to that childhood thing.
Coming back to that childhood thing. But as an engineer, what if we had a little robot?
You could program and tune, get to go to tumors and make drugs and do exactly what you want. You
could have it turn on when you wanted it to turn on. You could have it go where you wanted it to go.
We could use genetics to make bacteria be like that and be those little robots.
So how did you determine salmonella is that-
They're a vehicle.
Yeah, good. Okay. So there are two parts. First of all, it was shown in those early 2000 studies,
it was shown that they can make it safe and they can put it into people and it accumulated in
tumors. So that was the exciting thing there. It is very similar. It is the genetic cousin to E.
coli, which is the workhorse bacteria that everybody uses. So a lot of other bacteria
that people use for cancer are the different kinds of bacteria. They're very hard to manipulate
genetically. Salmonella is very easy to manipulate. So it gave me a vehicle that I
could tune very quickly and very reliably. So it is the form of salmonella you're using.
When it gets to the point, I guess I'm all over the place because I got so many questions.
Are you using it now on mice?
Oh, yes. Right.
Okay. So the salmonella is not affecting the mouse as a whole, it's just affecting and targeting
the cancer that's-
Okay.
Well, we're at the point now, you invited me to talk about this virus delivery,
but we have other salmonella that we're looking, we're talking to FDA about getting
a clinical trial to test it in people.
So what you found right here on the campus of UMass, are there labs around the country,
around the world doing the same research and you kind of beat them to it? Or do you work
in conjunction with other scientists across the world and together, this is what you've come up
with?
Both.
Right. So it's a bit competitive and a bit friendly at the same time.
And there's other bacteria species. There's been a couple of clinical trials with Listeria.
There's a current trial with Yersinia, which is what caused plague, but it works really well.
Right.
And just to give you an example, I've been working on this for 20 years and there's groups
in Korea and in Germany that also worked with salmonella.
And in Maine, this summer is going to be the first large conference that I'm actually the
chair of putting together all the people around the world who work on what I call microbial
therapies, like treating disease, not just cancer, but treating disease with microbes.
And so the answer to your question is sort of interesting.
We are very interested in this being a community as well as also kind of the reason we need to
compete with each other is it costs a lot of money to try these in people.
And investors want to see that you have a competitive edge.
And so you have to have intellectual property and you have to be able to show that you are
better, you are first.
And that's where the money comes from, the further they reach.
Right. And we need the money, even though my goal is to make something that improves society.
You cannot get things at the clinical trials without money.
And so in the process, we want to make sure that we can attract investors and people are
going to be interested in supporting this.
Wow.
We are up on our first commercial break.
Folks, stay with us.
Plenty more to talk about with this research, cancer research coming out of UMass Amherst.
We'll be back in just a moment.
This is 22 News In Focus with Patrick Berry.
Welcome back, everyone, to this edition of In Focus.
I'm your host, Patrick Berry.
Dr. Neil Forbes from the University of Massachusetts Amherst is sitting across
the desk from me.
The reason he is here is because he and his team have done some groundbreaking cancer
research by utilizing salmonella, which is a virus or is it?
That's bacteria.
It's bacteria.
Using the salmonella bacteria to fight liver and pancreatic cancer, two of the most dangerous
cancers out there.
So let's get back into the development of it.
So we talked about the global, your partnership with places around the world and trying to
beat others to market.
Where do you stand today with this research?
So you've been doing it in lab mice.
Yep.
What's next?
Next is, so I have a startup.
We've just come out of the lab.
It's called Ernest Pharmaceuticals.
And so we're at the fundraising stage.
And we have talked to FDA.
And we have a product.
We're ready to market.
And now it's just raising funds to do that first in human trial.
So you start with human trials first, obviously.
And then so you say bring it to market.
That could be how long?
Years?
Yeah, years.
It's the way all oncology drugs work.
So at this point, while we've shown that it's effective in animals, it usually takes eight
to 10 years to get it through human trials.
But that's to confirm that it's safe.
The first trials usually to confirm that it's safe, look for any indications that it might
be effective.
And then there's a larger trial to really show with statistics that it's functioning.
So of all the cancers that are out there, why liver and pancreatic?
Why those two specifically?
Why not prostate or lung or blastovium or whatever the brain cancer is that John McCain
died of?
Right.
Well, two reasons.
So the current research works in liver and pancreatic.
The virus that we're delivering works in those two tumors.
And they're deadly.
So we want to work on things that can make a difference in people's lives.
The life expectancy is very short for people who have liver and pancreatic cancer.
We want to be able to create therapies that can help people that really need it.
So is the idea behind this to cure liver and pancreatic cancers or to prolong the effects
of the cancers on the human body?
I would say both.
It's up until the kind of wave of new immune therapies, we never said the word cure.
It was like no cancer therapy ever cured.
And so we were always prolonging life.
Now we're hoping and we have a lot of immune stimulatory effects from the therapy we've
created.
So and we see cures in animals.
So we'd like to see cures in humans.
But we'd be very happy if we could see that we could extend life for people who have this
disease.
OK, so let's go back a little bit.
So you talk to me about the process of how it works.
So salmonella, how does the salmonella get to the tumor?
What modifications are made to the salmonella to make it fight it?
OK, so this would be an IV injection.
So and the advantage of IV is that we're looking to treat people who have late stage
cancer.
These are the ones that people who are usually like it's spread to the rest of the body.
And those tumors are hard to treat, hard to find.
When the bacteria get into the blood, they will actually accumulate in those sites of
where tumors are in other organs.
And they grow.
And strangely, they're protected by the tumor.
And they're cleared from the rest of the body.
And they only grow within the tumor.
So they attack it from the inside out?
They attack from the inside out.
That's exactly what they do.
And that was how I got started on this as an engineer was like, how could you get drugs
into tumors without treating the rest of the body?
If you get chemo, it affects the rest of your body.
That's why your hair falls out, why you get sick and nausea and have all these anti-nausea
drugs.
Here, what we have the bacteria, the one that we published recently that you drew me to
while I'm here, it's 50 million times more in tumors than it is in the organ, the liver
and spleen, which is what clears out bacteria.
What does that mean?
50 million more times.
That means that imagine you had a drug that had an effect that was killed cells.
It would kill 50 million cancer cells for one healthy cell.
So think about that from both how much more effective we can make it and how safer we
can make it.
Because now it's only working in the tumor and not in the rest of the body.
So it protects the rest of your organs from the treatment of the drug.
If you had a drug, if you were just taking chemotherapy and you were injecting it
intravenously, it would affect your whole body, which is why you see in your hair and
your intestines.
How does it know to go just to those two locations?
That's a really good question.
It comes back to that robotic.
Right.
No, that's partly the native bacteria and also partly what we do to make it work.
So it's a bit of a mix.
What happens is bacteria like to grow and they like kind of dying tissue.
So tumors are unusual and that they will be dead, dying tissue in a tumor.
Bacteria seek those spots out and then grow.
They would like to go anywhere else as well, but you have an immune system that clears
them out.
So in order for a tumor to grow, it has to also protect itself from the immune system.
So it sends immune suppression signals out and says, no, no, no, no.
There's nothing to see here and that there's nothing to see here allows the bacteria to
grow.
So we inject just a few bacteria.
They go into those sites of tumors.
They would go to the primary tumor that go to metastatic tissue and then they would grow
and that growth allows us to get this big difference in where they are.
So I got to check my notes because I want to make sure I pronounce this correctly.
Oncolytic viruses.
So oncolytic viruses is a whole other field.
Okay.
That I got interested in around 2018 and there are some on the market today that are being
used for treating melanoma.
They're what's really exciting about oncolytic viruses and this is not my primary field,
but this is what we've gotten interested in and this is what this publication is about
is that if you had, I've seen images of this.
If you have like a melanoma on your leg and you put this virus on it, it would train your
immune system to say, wait, wait, that immune suppression that you were being told.
No, no.
Look here.
It educates the immune system and then actually clears it from the rest of the body.
This is called the obscopal effect.
And this got people very, very excited about these things called oncolytic viruses that
you could prevent metastasis and you could prevent recurrence, but it only works in melanomas
because if you inject the virus into the blood, it gets cleared.
You have to, it works very well topically.
So right now they're doing this at least 50 human trials where they're injecting those
viruses directly into tumors.
But as I said before, that's not going to help with recurrence or metastasis because
you can't find every metastatic lesion.
And this is why patients that have metastatic disease are, their life expectancy is short
and they're scared.
So what the bacteria does by going to those sites, what we engineered, this is the crazy
part, is we made it so that we actually have the salmonella take the virus.
Salmonella don't usually carry viruses.
We have it so that they hold the virus genome and take it into those tumor sites and then
create a virus infection right in those sites.
My head is about to explode.
Thankfully, we're on our second commercial break.
Okay.
Stay with us, folks.
We'll be back in just a minute.
This is 22 News In Focus with Patrick Berry.
Welcome back, everyone, to this edition of In Focus.
I'm your host, Patrick Berry.
Sitting across the desk from me today is Dr. Neil Forbes.
He's a professor of chemical and biomolecular engineering at the University of Massachusetts
up in Amherst.
Dr. Forbes, thank you for joining me.
We've been talking about groundbreaking research that you and your department have been working
on when it comes to using what people are fearful of, the bacteria of salmonella, to
fight cancer, specifically two of the most deadly cancers, liver and pancreatic.
Before we went to break, we started to get into a little bit about how it works.
And I want you to continue telling me about that whole process.
Okay.
Let me give you a quick view of it.
Okay.
Sure.
Okay.
So, this is the cool part where we did a lot of engineering to make this happen.
We engineered the salmonella.
So, salmonella naturally likes to get inside cells to hide from the immune system, which
I mentioned before.
Our body is very sophisticated and we have lots of ways of getting rid of bacterial infections.
Salmonella have fought back and made their own way of hiding from the immune system by
going inside cells.
And we use that system.
We linked it to a cell death mechanism.
So, the bacteria, once they get inside a cell, they die and they break open.
So, they release their contents inside the cancer cell.
And what we did is we put then the virus genome into the salmonella so that once it releases
it, that genome goes into the nucleus of the cell and then makes copies of the virus.
And the researcher who did this, Shraddha Kunjada, it was an amazing amount of work
that she did.
And the trick is that salmonella also don't like having viruses.
And she edited all the antiviral mechanisms out of the salmonella so they could carry
the virus.
So, we have these pieces that make it so that it can carry it, it can transport it, and
it delivers it.
As I said at the beginning, when we were talking before, it goes only in tumors and then it
injects it only into cancer cells.
So, then all of those cancer cells now become sources of virus that then ultimately teaches
the immune system to then attack the tumor and clear it.
So, how long have you and your staff been working?
Oh, we've been working on-
You personally have been working with utilizing salmonella for 20-something years, but this
particular process of cancer fighting?
Yeah, we've been working on this virus strategy since about 2018.
So, this has turned around fairly quickly.
Fairly quickly, yeah.
Less than 10 years.
Yeah, right.
So, it was an incredible amount of work from really just one researcher who did an amazing
amount of work.
All of the engineering and all the animal studies and all the safety studies.
So, you kind of alluded to it.
It's you and one other person?
Just on this project, yes.
I have a team working on different projects, but the neat thing about salmonella is we
can easily tune them to do many different things.
We have salmonella that induce death pathways in cancer cells.
We have salmonella that retrain vaccines to then attack tumors.
We have salmonella that trick tumors into looking as if they've been killed by chemotherapy
and that then induces an immune response.
So, we have all these different strategies and they can all work together because salmonella
is a little bit like Legos.
We can build them to have multiple different functions and put them all together.
So, kind of fast forward.
So, do you foresee greater use of salmonella in the medical field to battle any human ailment?
Maybe not any, but all the ones where you want it to be in a certain spot.
Okay.
So, targeted.
Targeted therapies.
As you can see why cancer is the obvious place to start.
Right.
It affects a lot of people's lives and also it works really well in cancer.
I know of other people, my lab's not doing it, but working on wounds and intestinal issues
and lung infections.
So, there are cystic fibrosis.
There are many ways that we could use bacteria, not necessarily salmonella, but bacteria.
And then it's important to tune the organism you use for the indication that you want.
But I can imagine this becoming a very large field, almost Star Trek like, where now we
have the button, what disease do you have?
You could imagine having hundreds of different therapies that all work for
different people in different ways, depending on what they have and the characteristic of
their disease.
I know you're going to hate me for the question.
Timeline.
When do we think humans will be able to take advantage of this treatment to cure
liver pancreatic cancer?
10 years?
10 years.
Yeah.
I would really like this to be 10 years.
I think that we should see, there are trials going on right now that are a little farther
ahead.
We should see bacteria for cancer, hopefully in five or six.
Maybe we'll see this therapy.
You might see bacteria fighting other forms of cancer.
Other forms of cancer, right?
But this could be 10 years.
And then expanding it, there are already, two of the things that I talked about, there
is already bacteria on the market for intestinal disease.
There's also bacteria on the market for wounds.
So, this is coming and I'm really excited about it.
So, clearly, this is way over my head, but is this under the umbrella term of immunotherapy?
These are almost all immunotherapies, but they're not all immunotherapies.
And this is actually one of the really exciting things about this.
Immune is going to be, as we mentioned before, one of the ways we're probably going to see
cures in cancer.
But at the same time, we also need to directly kill cells.
So, this is why some of the strategies that I kind of mentioned briefly there, we want
to put them together.
So, we want to both trigger the immune system, but also directly be able to kill cells.
And if we can do those together, we'll be able to treat a larger group of patients.
Patients that are immune suppressive may not work with immune therapies, but we need other
strategies will work for them.
So, this is kind of what I was saying about having different tunable therapies.
My lab has these and they all work in animals right now.
So, the question really is just how can we get this to the market?
How can we get this into people's hands?
Fantastic.
Dr. Neil Forbes, I can't thank you enough for joining me today.
This has been a fascinating conversation.
I'm so excited more so that this research is being done right here in Western Massachusetts.
It's not Stanford or Minnesota.
It's you and your coworkers and staff are doing it right here in Western Massachusetts.
Thank you so very much for joining me today and talking about it.
Yeah.
Thank you for inviting me on.
This is fantastic.
Maybe we'll have you back.
That'd be great.
Okay.
Thank you.
